Biologic Therapy | No difference in death rates from biologics in RA patients

No Difference In Death Rates From RA Biologics Nancy Walsh writing in MedPage Today reported on a study published in Arthritis and Rheumatism showing that safety analysis of three "biologic" drugs for rheumatoid arthritis found no difference in terms of risk of death for the patients who use them." The analysis, compared the three biologics: Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab). After five years, "the researchers found no difference in death rates among the three drugs," and that the overall death rate was low. This is a study that confirms the notion that the risk of death due to these drugs is low. Nonetheless, it is still important to realize these are powerful drugs that need close monitoring.